Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort Study

Abstract

Letters20 July 2020Characteristics and Mortality of Hospitalized Patients With COVID-19 in Iran: A National Retrospective Cohort StudyFREEMohammad Jalili, MD, Pooya Payandemehr, MD, Abbas Saghaei, MD, Hassan Nouri Sari, MD, Hamidreza Safikhani, MD, and Pirhossein Kolivand, PhDMohammad Jalili, MDTehran University of Medical Sciences, Tehran, Iran (M.J.), Pooya Payandemehr, MDSina Hospital, Tehran University of Medical Sciences, Tehran, Iran (P.P.), Abbas Saghaei, MDIslamic Azad University, Tehran, Iran (A.S.), Hassan Nouri Sari, MDNational Emergency Medical Organization, Tehran, Iran (H.N.S., P.K.), Hamidreza Safikhani, MDInformation Technology Center, MOHME, Tehran, Iran (H.S.), and Pirhossein Kolivand, PhDNational Emergency Medical Organization, Tehran, Iran (H.N.S., P.K.)Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M20-2911 SectionsAboutVisual AbstractPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Background: Coronavirus disease 2019 (COVID-19) is a serious health care concern in Iran, with 259 652 confirmed cases since the first report on 18 February 2020, and Iran has the ninth highest national death toll in the world, with more than 13 000 deaths (1). Despite the immensity of the problem, there are limited data available about the characteristics and mortality of hospitalized patients in Iran.Objective: To assess the characteristics and mortality of hospitalized patients with COVID-19 in Iran.Methods and Findings: The Medical Care Monitoring Center of the Ministry of Health and Medical Education (MOHME) of Iran mandated all hospitals to register patients admitted with a diagnosis of confirmed or suspected COVID-19 in a national registry. The registry included patient demographic characteristics, coexisting diseases, and presenting signs and symptoms. Fever and hypoxemia were evaluated by the health care provider, and other variables were reported by the patient. The Information Technology Center of MOHME provided access to this database.In this retrospective cohort study, we enrolled all consecutively hospitalized adults and children with laboratory-confirmed COVID-19 who were admitted to any of the 1034 hospitals in Iran from 20 February to 20 April 2020. We defined laboratory confirmation as at least 1 positive result on real-time reverse transcriptase polymerase chain reaction assay of a specimen collected on a nasopharyngeal swab according to World Health Organization protocols. Patients who had a negative or pending test result at the cutoff of the study period were excluded. Pregnant patients were also excluded.The institutional review board of Tehran University of Medical Sciences approved the study protocol. The requirement for informed consent was waived because this study was regarded as minimal-risk research using data collected for routine clinical practice. Furthermore, researchers analyzed only deidentified data.We used the Kaplan–Meier method to estimate the probability of death (final event) from the date of hospital entry (starting event). Patients who had been discharged were assumed to be alive at the end of the study period; those who had been discharged or were still hospitalized at the study closeout were censored, and the last day of the study period was used to compute the time at risk.Among 62 955 patients admitted to the designated hospitals during the study period, 29 111 tested positive for severe acute respiratory syndrome coronavirus 2. A total of 130 were excluded because of pregnancy, leaving 28 981 patients in the study population. At study closeout, 23 367 patients had either been discharged or died. Patients' demographic and clinical characteristics are shown in Table 1. Overall, 23 367 patients had a definitive outcome during the study period. When all patients admitted during the study period were used in the Kaplan–Meier analysis of survival, the cumulative risk for in-hospital mortality in 30 days was 24.4%. Table 2 presents the 30-day risk for death in different patient groups.Table 1. Demographic and Clinical Characteristics of Hospitalized Patients With Laboratory-Confirmed COVID-19Table 2. Cumulative Risk for Death in 30 Days Among 28 981 Patients With Confirmed COVID-19 Hospitalized During the Study Period, Calculated by Kaplan–Meier AnalysisDiscussion: We describe the characteristics and mortality among hospitalized patients with laboratory-confirmed COVID-19 in Iran. The high case-fatality rate we saw is consistent with the hospitalized population; milder cases were likely excluded. Consistent with other studies, hypoxemia, fever, and cough were common presenting symptoms, as were comorbidities (2–5).Although this was a large nationwide study that evaluated patients with laboratory-confirmed COVID-19, it has several notable limitations. The study population is from 1 country. Criteria for hospitalization may vary among countries, and this may make it difficult to compare mortality rates. Most of the patient variables were self-reported and could not be verified. Although guidelines on how to record data in the database were provided, no assessment of interrater reliability was done, and reporting among hospitals may have varied. Moreover, this national database lacks detailed clinical information. Our database included only the admission data, and we did not have access to the exact time of symptom onset or patients' data during hospitalization. Some symptoms not initially recognized as presentations of COVID-19 (for example, anosmia) were not included in this registry from the beginning, so we did not have those data for all participants. Although national guidelines are in place, we have no data to compare the quality of the diagnostic and therapeutic measures in different hospitals. Active follow-up of discharged patients to ascertain vital status was not feasible, but we believe it is unlikely that a discharged patient died without returning to a designated hospital, where they would be registered again in the national database. Further studies are required to identify independent predictors of mortality for patients with COVID-19.References1. World Health Organization. Coronavirus disease (COVID-2019) situation reports. Accessed at www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports on 2 May 2020. Google Scholar2. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J. 2020;55. [PMID: 32269088] doi:10.1183/13993003.00524-2020 CrossrefMedlineGoogle Scholar3. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054-1062. [PMID: 32171076] doi:10.1016/S0140-6736(20)30566-3 CrossrefMedlineGoogle Scholar4. Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis. 2020. [PMID: 32211844] doi:10.1093/cid/ciaa242 CrossrefMedlineGoogle Scholar5. Liang WH, Guan WJ, Li CC, et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020;55. [PMID: 32269086] doi:10.1183/13993003.00562-2020 CrossrefMedlineGoogle Scholar Comments 0 Comments Sign In to Submit A Comment Author, Article, and Disclosure InformationAuthors: Mohammad Jalili, MD; Pooya Payandemehr, MD; Abbas Saghaei, MD; Hassan Nouri Sari, MD; Hamidreza Safikhani, MD; Pirhossein Kolivand, PhDAffiliations: Tehran University of Medical Sciences, Tehran, Iran (M.J.)Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran (P.P.)Islamic Azad University, Tehran, Iran (A.S.)National Emergency Medical Organization, Tehran, Iran (H.N.S., P.K.)Information Technology Center, MOHME, Tehran, Iran (H.S.)Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M20-2911.Reproducible Research Statement: Study protocol: Available from Dr. Jalili (e-mail, [email protected]). Statistical code and data set: Not available.Corresponding Author: Mohammad Jalili, MD, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Keshavarz Boulevard, Tehran, Iran; e-mail, [email protected] article was published at Annals.org on 20 July 2020. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byDemographics, clinical characteristics, and outcomes in hospitalized patients during six waves of COVID‑19 in Northern Iran: a large cohort studyEffect of a home-based exercise programme on mental health and well-being in children during COVID-19 pandemicThe interface between SARS-CoV-2 and non-communicable diseases (NCDs) in a high HIV/TB burden district level hospital setting, Cape Town, South AfricaInvestigating the Association between COVID-19 Prognosis and Demographic and Clinical Features, Underlying Diseases, and Drug and Supplement Use in Patients Hospitalized in Zabol, Iran: A Single-Center Retrospective StudyCoronavirus Disease-2019 PneumoniaClinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in IndonesiaEvidence-Based Design in the Hospital Environment: A Staff’s Burnout Study in the COVID-19 EraComorbid Asthma Increased the Risk for COVID-19 Mortality in Asia: A Meta-AnalysisClinical characteristics and mortality associated with COVID-19 at high altitude: a cohort of 5161 patients in Bogotá, ColombiaDemographics, clinical characteristics, and outcomes of 27,256 hospitalized COVID-19 patients in Kermanshah Province, Iran: a retrospective one-year cohort studyFactors associated with survival of Iranian patients with COVID-19: comparison of Cox regression and mixture cure modelNational geographical pattern of COVID-19 hospitalization, case fatalities, and associated factors in patients covered by Iran Health Insurance OrganizationCoronavirus disease-related in-hospital mortality: a cohort study in a private healthcare network in BrazilMedications Associated with Lower Mortality in a SARS-CoV-2 Positive Cohort of 26,508 VeteransThe return visit, outcome and predicting factors of return visit among suspected COVID-19 outpatientsThe Evaluation of Diagnostic Values of Clinical Symptoms for COVID-19 Hospitalized Patients in Northern Iran: The Syndromic Surveillance System DataThe German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristicsCardiopulmonary Imaging Utilization and Findings among Hospitalized COVID-19 Patients in Latin AmericaCase fatality and mortality rates, socio‐demographic profile, and clinical features of COVID‐19 in the elderly population: A population‐based registry study in IranClinical and Epidemiological Features of COVID-19 Patients in Rafsanjan County, Iran: A Secondary Data based StudyASSESSMENT OF DEPENDENCY-ASSOCIATED FINANCIAL BURDEN OF COVID-19 MORTALITIESObstructive lung diseases burden and COVID-19 in developing countries: a perspectiveCOVID-19 infection in an intensive care unit in Tunisia: Risk factors of mortalityAcute Respiratory Failure and Mechanical Ventilation in Women With COVID-19 During PregnancySociodemographic determinants and clinical risk factors associated with COVID-19 severity: a cross-sectional analysis of over 200,000 patients in Tehran, IranCOVID-19 in Liver and Kidney Transplant Recipients: An Initial Single-center Experience in IranIgM-enriched immunoglobulin in COVID-19: Case series of 15 severely ill SARS-CoV-2-infected patientsEpidemiological, imaging, laboratory, and clinical characteristics and factors related to mortality in patients with COVID-19: a single-center studyDiabesity Associates with Poor COVID-19 Outcomes among Hospitalized PatientsAsthma in patients with coronavirus disease 2019The risk factors of COVID-19 in 50–74 years old people: a longitudinal population-based studyCOPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysisClinical features and mortality in COVID-19 SARI versus non COVID-19 SARI cases from Western Rajasthan, IndiaIntermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studiesThe use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trialAge, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective studyAge, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study January 2021Volume 174, Issue 1 Page: 125-127 Keywords Cohort studies COVID-19 Databases Fevers Hospitalizations Hypoxia Mortality Pregnancy Statistical data Survival analysis ePublished: 20 July 2020 Issue Published: January 2021 Copyright & PermissionsCopyright © 2020 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Topics & Concepts